研究#2019-0079
Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies
MD安德森学习状况
不接受
治疗剂
tabelecleucel
描述
该方案的主要目的是向患有爱泼斯坦 - 巴尔病毒相关疾病和恶性肿瘤的参与者提供扩展的对Tabelecleucel的访问权限,而这些疾病和恶性肿瘤没有其他适当的治疗选择,并且不符合旨在支持开发的临床研究的资格。和Tabelecleucel的注册。
Information and next steps
疾病:
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Epstein-Barr Viremia, Lymphoma, AIDS-related, Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD)带有原发性免疫缺陷(PID),平滑肌肉瘤(LMS),鼻咽癌(NPC),Epstein-Barr病毒相关淋巴细胞增生性疾病(EBV+ LPD)具有获得性免疫缺陷(AID),固体器官移植并发症,茎细胞移植并发症,
Study phase:
不适用
Physician name:
Sajad Khazal
Department:
儿科
For general questions about clinical trials:
1-877-632-6789
帮助#endcancer
Give Now
Your gift will help make a tremendous difference.
献血
Our patients depend on blood and platelet donations.